These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18723565)

  • 1. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Wijbrandts CA; van Leuven SI; Boom HD; Gerlag DM; Stroes EG; Kastelein JJ; Tak PP
    Ann Rheum Dis; 2009 Aug; 68(8):1316-21. PubMed ID: 18723565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation.
    Herenius MM; Oliveira AS; Wijbrandts CA; Gerlag DM; Tak PP; Lebre MC
    PLoS One; 2013; 8(2):e57802. PubMed ID: 23460910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis.
    Soubrier M; Jouanel P; Mathieu S; Poujol D; Claus D; Dubost JJ; Ristori JM
    Joint Bone Spine; 2008 Jan; 75(1):22-4. PubMed ID: 17888710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S; McColl G; Wicks IP
    Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adalimumab therapy on disease activity and interferon-γ-mediated biochemical pathways in patients with rheumatoid arthritis.
    Kurz K; Herold M; Winkler C; Klotz W; Russe E; Fuchs D
    Autoimmunity; 2011 May; 44(3):235-42. PubMed ID: 21434757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab.
    Filippucci E; Iagnocco A; Salaffi F; Cerioni A; Valesini G; Grassi W
    Ann Rheum Dis; 2006 Nov; 65(11):1433-7. PubMed ID: 16504996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
    Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
    Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
    Plant D; Ibrahim I; Lunt M; Eyre S; Flynn E; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
    Arthritis Res Ther; 2012 Oct; 14(5):R214. PubMed ID: 23039402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA; Klaasen R; Dijkgraaf MG; Gerlag DM; van Eck-Smit BL; Tak PP
    Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
    Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
    Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.
    Brennan-Bourdon LM; De la Cruz-Mosso U; Reyes-Castillo Z; Martínez-Bonilla GE; Ramírez-Dueñas MG; Islas-Carbajal MC; Rincón-Sánchez AR; Salazar-Páramo M; Muñoz-Valle JF
    Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):207-13. PubMed ID: 25721154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
    Peters MJ; Vis M; van Halm VP; Wolbink GJ; Voskuyl AE; Lems WF; Dijkmans BA; Twisk JW; de Koning MH; van de Stadt RJ; Nurmohamed MT
    Ann Rheum Dis; 2007 Jul; 66(7):958-61. PubMed ID: 17314120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
    Cuchacovich M; Soto L; Edwardes M; Gutierrez M; Llanos C; Pacheco D; Sabugo F; Alamo M; Fuentealba C; Villanueva L; Gatica H; Schiattino I; Salazaro L; Catalan D; Valenzuela O; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2006; 35(6):435-40. PubMed ID: 17343250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.